← boardnext 2026-07-31next 2026-09-27next 2026-12-01next 2027-05-20next 2027-08-07next 2027-11-16next 2028-06-23next 2034-07-28
BIIB
Biogendistress 2/10 · well-funded / low risk$197.600%today-9% from 52w high
Lead: Muscular Atrophy
Revenue
$2478M
Liquidity
$3383M
Runway
—
Shares 1y
+1%
Price & events
+13.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
-5.4%
1W
+0.2%
1M
+5.2%
3M
+15.2%
6M
+50.9%
1Y
-11.9%
2Y
-39.3%
5Y
-18.7%
All
Overview
- Market Cap
- $29.17B
- Enterprise Value
- $32.08B
- Volume
- 35.70K
- 52 Week Range
- $123 – $217
- Total Shares
- 147.64M
- Float Shares
- 147.18M
- Short %
- 4.32%
- % Held by Insiders
- 0.19%
- % Held by Institutions
- 96.31%
- RVOL
- 0.03x
- Beta
- 0.16
Pipeline stages · 8 programs
Nusinersen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Litifilimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Felzartamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BIIB017 (peginterferon beta-1a), Interferon beta type 1a
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tofersen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Omaveloxolone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Salanersen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Diroximel Fumarate, Dimethyl Fumarate, Fingolimod
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 19 trials · 19 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-31 Estimated 50% readout ~2026-10-14 | Phase 3 | Nusinersen | Muscular Atrophy, Spinal | — | active not recruiting |
| 2026-09-27 Estimated 50% readout ~2026-12-11 | Phase 3 | Litifilimab | Lupus Erythematosus, Systemic | — | active not recruiting |
| 2026-09-30 Estimated 50% readout ~2026-12-14 | Phase 3 | Litifilimab | Lupus Erythematosus, Systemic | — | active not recruiting |
| 2026-10-20 Estimated 50% readout ~2027-01-03 | Phase 2/3 | Litifilimab | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | — | active not recruiting |
| 2026-12-01 Estimated 50% readout ~2027-02-14 | Phase 3 | Felzartamab | Antibody-mediated Rejection | — | active not recruiting |
Show all 19 trials · 14 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05-20 Estimated 50% readout ~2027-08-03 | Phase 3 | BIIB017 (peginterferon beta-1a), Interferon beta type 1a | Multiple Sclerosis, Relapsing-Remitting | — | active not recruiting |
| 2027-05-31 Estimated 50% readout ~2027-08-14 | Phase 3 | Felzartamab | Immunoglobulin A Nephropathy (IgAN) | — | recruiting |
| 2027-08-07 Estimated 50% readout ~2027-10-21 | Phase 3 | Tofersen | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | — | active not recruiting |
| 2027-09-24 Estimated 50% readout ~2027-12-08 | Phase 3 | Nusinersen | Spinal Muscular Atrophy | — | active not recruiting |
| 2027-11-16 Estimated 50% readout ~2028-01-30 | Phase 3 | Omaveloxolone | Friedreich Ataxia | — | recruiting |
| 2028-02-10 Estimated 50% readout ~2028-03-26 | Phase 2 | Felzartamab | Microvascular Inflammation | — | recruiting |
| 2028-06-23 Estimated 50% readout ~2028-09-06 | Phase 3 | Salanersen | Spinal Muscular Atrophy | — | recruiting |
| 2028-11-28 Estimated 50% readout ~2029-02-11 | Phase 3 | Salanersen | Muscular Atrophy, Spinal | — | recruiting |
| 2028-12-29 Estimated 50% readout ~2029-03-14 | Phase 3 | Felzartamab, Tacrolimus, Standard of Care IST | Primary Membranous Nephropathy | — | recruiting |
| 2029-06-26 Estimated 50% readout ~2029-09-09 | Phase 3 | BIIB059 (litifilimab) | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | — | enrolling by invitation |
| 2029-07-27 Estimated 50% readout ~2029-10-10 | Phase 3 | Salanersen | Muscular Atrophy, Spinal | — | not yet recruiting |
| 2030-03-29 Estimated 50% readout ~2030-06-12 | Phase 3 | Litifilimab | Systemic Lupus Erythematosus (SLE) | — | enrolling by invitation |
| 2031-05-28 Estimated 50% readout ~2031-08-11 | Phase 3 | Felzartamab | Antibody-mediated Rejection, Microvascular Inflammation | — | enrolling by invitation |
| 2034-07-28 Estimated 50% readout ~2034-10-11 | Phase 3 | Diroximel Fumarate, Dimethyl Fumarate, Fingolimod | Relapsing Forms of Multiple Sclerosis | — | not yet recruiting |
Catalyst news & presentations · 4
- 2026Guided 40%conferencedata presentationsecondaryLitifilimab · Presentation of Phase 2 trial results at the 2026 AAD Annual Meeting.PR wire
- 2026-07-29Confirmed 100%earningsEarningsEarnings releaseyahoo
- 2026-05-14partnershipSYFOVRE · Biogen completes acquisition of Apellis, accepting all tendered shares and executing a CVR agreement for SYFOVRE sales milestones.SEC 8-K
- 2026-03-31partnershipBiogen agrees to acquire Apellis via tender offer at $41.00/share plus CVR, closing by Sept 30, 2026.SEC 8-K
Approved drugs (8)
- ZURZUVAEZURANOLONE2023 · Prescription
- SKYCLARYSOMAVELOXOLONE2023 · Prescription
- ADUHELMADUCANUMAB-AVWA2021 · Prescription
- VUMERITYDIROXIMEL FUMARATE2019 · Prescription
- SPINRAZANUSINERSEN SODIUM2016 · Prescription
- ZINBRYTADACLIZUMAB2016 · Prescription
- TECFIDERADIMETHYL FUMARATE2013 · Prescription
- AVONEXINTERFERON BETA-1A1996 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $226 (+15% upside) · 30 analysts
- 2026-07-21GuggenheimBuy
- 2026-07-21B of A SecuritiesNeutral
- 2026-07-13Truist SecuritiesHold → Buy
- 2026-07-08Morgan StanleyEqual-Weight
- 2026-07-07RBC CapitalOutperform
- 2026-06-29NeedhamBuy
Competitors — Muscular Atrophy
Recent news
- 2026-07-22Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
- 2026-07-22Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
- 2026-07-22Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
- 2026-07-21Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
- 2026-07-21Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
- 2026-07-21Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
- 2026-07-21BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
- 2026-07-21Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.